Skip to main content

Baxter International guidance

  • BAX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$25.54−1.05%Close 16 Nov 2026 · Market value $13.38B

In its results release of 29 Oct 2026 (Q3 FY2026), Baxter International gave 2 forecasts in figures, among them EPS (adjusted) of $2.05 to $2.15 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
Organic revenue growthFY2026+3% to +4%Organic sales growth from continuing operations: 3% to 4% (previously 2% to 3%)
EPS · AdjustedFY2026$2.05 to $2.15Adjusted diluted EPS $2.05 - $2.15

Source: the company's earnings release.

Guidance against results above 1 · within 0 · below 1

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Organic revenue growthFY2026+3% to +4%Raised once—To come
EPS · AdjustedFY2026$2.05 to $2.15Raised twice—To come
EPS · AdjustedQ4 FY2025$0.52 to $0.57Given once$0.44Below the range
EPS · AdjustedQ3 FY2025$0.58 to $0.62Given once$0.69Above the range
Revenue growthFY2024+1% to +2%Given once+2.66%Above the range

BAX in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.